Cancer Prevention and Interception: A New Era for Chemopreventive Approaches
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
At several recent, internationally attended scientific meetings, including the American Association for Cancer Research (AACR)'s “Shaping the Future of Cancer Prevention: A Roadmap for Integrative Cancer Science and Public Health” summit in Leesburg (VA) and the AACR Annual Meeting in New Orleans, the focus on cancer prevention to reduce cancer-related deaths was extensively discussed with renewed attention and emphasis. Cancer prevention should be actively proposed even to healthy individuals, and not just to individuals with high cancer risk. We discuss evaluation of a high cancer risk versus the relatively low risk for side effects of chemopreventive agents. The concept of cancer interception, which is halting transformed cells from becoming malignant cancers, should be adopted for cancer prevention. Potential prevention/interception actions include adopting healthy life style and avoiding carcinogens, repressing inflammation and pathologic angiogenesis, controlling metabolism, correcting insulin resistance and other metabolic alterations. Current drugs with limited toxicity can be repurposed to reduce cancer incidence. Aspirin is now being recommended for the prevention of colorectal cancer and it prevents other neoplasms as well. Metformin and β-blockers could be valuable for reducing pancreatic and breast cancer onset. On the basis of the evaluation of cancer risk, we here call for personalized approaches for cancer prevention and preventive interception and we envisage a list of measures and potential guidelines for preventive and interceptive strategies to reduce cancer burden. Investment into translational research to bring these approaches into public health policies and in the clinic is urgently needed. Clin Cancer Res; 22(17); 4322–7. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variation in cancer risk among tissues can be explained by the number of stem cell divisions
Tomasetti, C., & Vogelstein, B. (2015) · Science · doi:10.1126/science.1260825 · Cited by 1,927 · cited 1×
“" A provocative article in early 2015 implied that the majority of cancers are due to chance, rather than predictable causes (23).”
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497 · cited 1×
“Chemoprevention among tobaccousers could be applied (33); for example, long-term use of aspirin has been found to substantially reduce deaths due to adenocarcinomas of the lung, esophagus, and colorectum (22), all enhanced in smokers.”
BackgroundThe Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Cancer risk: Role of environment
Ashford, N. A., Bauman, P., Brown, H. S., Clapp, R. W., Finkel, A. M., Gee, D., Hattis, D. B., Martuzzi, M., Sasco, A. J., & Sass, J. B. (2015) · Science · doi:10.1126/science.aaa6246 · Cited by 67
Cited by
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Self-citationScafoglio, C. R., Villegas, B., Abdelhady, G., Bailey, S. T., Liu, J., Shirali, A. S., Wallace, W. D., Magyar, C. E., Grogan, T. R., Elashoff, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat5933 · Cited by 176
“Recently, intensive research efforts have been directed to the elucidation of the molecular mechanisms of pulmonary premalignancy development and progression (5–7) to find signatures of premalignancy that can be targeted for early diagnosis and cancer chemoprevention/interception (8, 9).”
BackgroundHao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216603 · Cited by 55
Teper, Y., Ye, L., Waldron, R. T., Lugea, A., Sun, X., Sinnett-Smith, J., Hines, O. J., Pandol, S. J., Rozengurt, E., & Eibl, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-43498-9 · Cited by 10
Ako, S., Teper, Y., Ye, L., Sinnett-Smith, J., Hines, O. J., Rozengurt, E., & Eibl, G. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.04.012 · Cited by 3
“2 This is particularly important as the incidence and mortality of PDAC is expected to rise, 3 which may be caused largely or at least partially due to the high and rising prevalence of obesity in US adults and children.”
Metadata
- Authors
- Albini, A., DeCensi, A., Cavalli, F., & Costa, A.
- Venue
- Clinical Cancer Research
- Published
- 2016-08-31
- Volume
- 22
- Issue
- 17
- Pages
- 4322-4327
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2403180991
- Cited by
- 56
- References
- 4
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer Prevention and Interception: A New Era for Chemopreventive Approaches. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0695
- The paper
- Albini, A., DeCensi, A., Cavalli, F., & Costa, A. (2016). Cancer Prevention and Interception: A New Era for Chemopreventive Approaches. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0695
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.